The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 5×
“Such clinical studies have shown that the use of trastuzumab in combination with chemotherapy provides significant clinical benefits, including a significant increase in survival, in patients with HER2positive metastatic breast cancer [7].”
BackgroundResultInfluential(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Self-citationPegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Cardenal, F., López-Cabrerizo, M. P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.12 · Cited by 471
Molecular abnormalities in lung cancer.
Salgia, R., & Skarin, A. T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1207 · Cited by 276
[Molecular abnormalities in lung cancer].
Shimizu, S., & Mitsudomi, T. (2002) · PubMed · Cited by 235
Cancer prevalence in European registry areas
Micheli, A., Mugno, E., Krogh, V., Quinn, M. J., Coleman, M., Hakulinen, T., Gatta, G., Berrino, F., & Capocaccia, R. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf127 · Cited by 195
Kern, J. A., Slebos, R. J., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., & Schwartz, D. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117001 · Cited by 182
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
Cook-Bruns, N. (2001) · Oncology · doi:10.1159/000055403 · Cited by 158
Bunn, P. A., Helfrich, B., Soriano, A., Franklin, W. A., Varella‐Garcia, M., Hirsch, F. R., Barón, A. E., Zeng, C., & Chan, D. C. F. (2001) · PubMed · Cited by 152
Novel Targets for Lung Cancer Therapy: Part I
Dy, G. K., & Adjei, A. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.145 · Cited by 139
Doxorubicin-induced cardiomyopathy
(1984) · Reactions Weekly · doi:10.1007/bf03273255 · Cited by 139
Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer
Shi, D., He, G., Cao, S., et al. (1992) · Molecular Carcinogenesis · doi:10.1002/mc.2940050308 · Cited by 128
HER2/neu expression in malignant lung tumors
Hirsch, F. R., Franklin, W. A., Veve, R., Varella‐Garcia, M., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31523 · Cited by 102
The role of HER-2 expression in predicting response to therapy in breast cancer.
MASS, R. D. (2000) · PubMed · Cited by 92
Herceptest: Her2 expression and gene amplification in non-small cell lung cancer
Cox, G., Vyberg, M., Melgaard, B., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1214 · Cited by 85
Small, E. S., Bok, R., Reese, D., Sudilovsky, D., & Frohlich, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90159-9 · Cited by 55
HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
Scheurle, D., Jahanzeb, M., Aronsohn, R. S., et al. (2000) · PubMed · Cited by 54
Noguchi, M., Murakami, M., Bennett, W. P., Lupu, R., Hui, F., Harris, C. C., & Gerwin, B. I. (1993) · PubMed · Cited by 47
Cited by
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Metadata
- Authors
- Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 15
- Issue
- 1
- Pages
- 19-27
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2133208325
- Cited by
- 388
- References
- 27
- FWCI
- 16.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.